Atea Pharmaceuticals (AVIR) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Prothena (PRTA) over the past year, gaining 68.7% versus a loss of 16.6%. Over five years, PRTA leads with a -86.6% price change compared with -87.2% for AVIR. Prothena is the larger company by market cap ($435.3 million vs $401.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | PRTA |
|---|---|---|
| Share price | $5.01 | $8.48 |
| Market cap | $401.83M | $435.34M |
| 1-day change | -1.18% | +5.74% |
| YTD return | +40.34% | -11.20% |
| 1-year return | +68.69% | -16.62% |
| 5-year return | -87.25% | -86.64% |
| EPS (TTM) | $-2.07 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $11.80 |
| 52-week low | $2.87 | $7.73 |
| Distance from 52-week high | -22.33% | -28.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +88.02% | +152.36% |
| Average volume | 298.92K | 478.70K |
| Shares outstanding | 80.20M | 51.34M |
| Employees | 55 | 67 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed PRTA by 85.3 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Healthcare · Biotechnology · 55 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
AVIR vs PRTA FAQ
Which is bigger, Atea Pharmaceuticals or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $435.34M compared with $401.83M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or PRTA?
AVIR returned +68.69% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Prothena in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.